ALX Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026
Rhea-AI Summary
ALX Oncology (Nasdaq: ALXO) will report fourth quarter and full year 2025 financial results and provide a business update on Friday, February 27, 2026 before market open.
The company will host a teleconference and live audio webcast at 5:30am PT / 8:30am ET; a replay and corporate presentation will be archived on the investor section of the company website.
Positive
- None.
Negative
- None.
News Market Reaction – ALXO
On the day this news was published, ALXO gained 8.19%, reflecting a notable positive market reaction. Argus tracked a peak move of +9.5% during that session. Our momentum scanner triggered 22 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $26M to the company's valuation, bringing the market cap to $348M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
ALXO gained 2.2% while peers showed mixed moves: ARTV and CUE were up, whereas INKT, APLT, and HOWL declined. With peers moving in both directions, this points to stock-specific dynamics rather than a synchronized biotech move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 30 | Equity offering | Negative | +10.8% | Underwritten share and warrant offering raising about $150M gross proceeds. |
| Jan 30 | Clinical data update | Positive | +10.8% | Exploratory Phase 1b/2 data linking CD47 expression to evorpacept response. |
| Jan 08 | Conference presentation | Neutral | +5.1% | Corporate presentation and fireside chat at J.P. Morgan Healthcare Conference. |
| Jan 08 | Trial advancement | Positive | +5.1% | Progress in ASPEN-09 breast cancer trial and ALX2004 Phase 1 dose escalation. |
| Dec 07 | Positive trial results | Positive | +1.4% | Investigator-sponsored Phase 2 lymphoma data showing high CR and ORR with evorpacept. |
Recent news, including positive clinical data and even a dilutive offering, has typically been followed by upward price reactions.
Over the last few months, ALXO has combined capital raising with steady clinical and corporate progress. A late January 2026 underwritten offering raised about $150 million, yet shares rose over 10% alongside new biomarker data for evorpacept. Earlier in January 2026, the company highlighted advancement of the ASPEN‑09 breast cancer trial and its ALX2004 ADC, and presented at the J.P. Morgan Healthcare Conference, with shares reacting positively. The current earnings-date announcement follows this period of financing, insider buying, and favorable trial updates.
Market Pulse Summary
The stock moved +8.2% in the session following this news. A strong positive reaction aligns with a stock that has recently responded well to news, including clinical updates and corporate events. Prior announcements in December 2025 and January 2026 produced generally positive price moves, even around financing. However, new highs after earnings dates can be vulnerable if results or guidance disappoint or if prior gains already reflect optimism, so investors have watched how post-event trading compared with these earlier reactions.
AI-generated analysis. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology"; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced plans to report its fourth quarter and full year 2025 financial results and a business update on Friday, February 27th, 2026 before market open. The company will host a teleconference in conjunction with its financial results press release.
Fourth Quarter and Full Year 2025 Results Webcast Information
Date & Time: Friday, February 27, 2026 at 5:30am PT / 8:30am ET
Webcast Access: https://viavid.webcasts.com/starthere.jsp?ei=1753123&tp_key=d6cfaba210
Participant Listening Options by Phone: To access the conference call, please dial 1-877- 407-0755 or +1-201-389-0913 and ask to be joined into the ALX Oncology Fourth Quarter and Full Year 2025 Financial Results Conference Call.
Another option for instant telephone access to the event is to use the Call me™ link below:
https://callme.viavid.com/viavid/?callme=true&passcode=13755276&h=true&info=company&r=true&B=6
A live audio webcast of the call, along with the ALX Oncology corporate presentation, will be available under "Events & Presentations" in the Investor section of the Company's website, www.alxoncology.com. An archived webcast will be available on the Company's website after the event.
About ALX Oncology
ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives. ALX Oncology’s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications. ALX Oncology’s second pipeline candidate, ALX2004, is a novel EGFR-targeted antibody-drug conjugate with a differentiated mechanism of action. A Phase 1 dose-escalation trial of ALX2004 is ongoing in patients with EGFR-expressing solid tumors. More information is available at www.alxoncology.com and on LinkedIn @ALX Oncology.
Investor Relations Contact:
Elhan Webb, CFA, IR Consultant
ewebb@alxoncology.com
Media Contact:
Michele Parisi, SparkPoint Healthcare Communications
mparisi@sparkpointpr.com
(925) 864-5028
FAQ
When will ALX Oncology (ALXO) report Q4 and full year 2025 results?
How can investors listen to the ALX Oncology (ALXO) earnings call on February 27, 2026?
Where will the ALX Oncology (ALXO) presentation and archived webcast be available?
What time is the ALX Oncology (ALXO) teleconference on February 27, 2026?
Is there an instant phone access option for the ALX Oncology (ALXO) earnings call?
Will ALX Oncology (ALXO) provide a replay of the February 27, 2026 webcast?
